glp-1 dual agonist Efficacy of glucagon-like peptide-1 and estrogen in pancreatic islets protection and pre-clinical models of insulin-deficient diabetes Mechanisms of action and effects
Description
35% relative risk reduction), and death from any cause (5.7% and 8.3%, respectively

Regular follow-up visits check effectiveness and safety, while also combining dietary coaching, activity planning and behavioral support to help maintain the results
Results Search and risk of bias Of the 54 articles assessed for eligibility, 23 RCTs (References 123 in the Additional file 1) fulfilled the inclusion criteria and were included in the meta-analysis (Additional file 1: Fig

To our knowledge, only one trial on the efficacy of the combination of multiple agonists in the treatment of NAFLD in humans is available to date

Inflammation in obesity-related HFpEF: the STEPHFpEF program

Tauqeer Z, Bracha P, Hua P, Yu Y, Cui QN, VanderBeek BL
